2,4-二氧代-4-吡啶-4-丁酸甲酯 | 374063-91-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 中文名称: 2,4-二氧代-4-吡啶-4-丁酸甲酯
• 英文名称: methyl 2,4-dioxo-4-(pyridin-4-yl)butanoate
• 英文别名: methyl 2,4-dioxo-4-pyridin-4-ylbutanoate
• CAS: 374063-91-9
• 化学式: C₁₀H₉NO₄
• mdl: MFCD06245329
• 分子量: 207.186
• InChiKey: WOCFUTQLECHXPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  73.3
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 危险品标志：
  T
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温、密封、干燥

反应信息

• 作为反应物：
  描述：

  2,4-二氧代-4-吡啶-4-丁酸甲酯 在 一水合肼 作用下， 以 甲醇 为溶剂， 生成 1-phenyl-5-(pyridin-4-yl)-1H-pyrazole-3-carbohydrazide
  参考文献：
  名称：

  Design, Synthesis and Antimicrobial Evaluation of Methyl Pyridyl-2,4- Dioxobutanoates and Some New Derived Ring Systems

  摘要：

  本研究描述了一系列新化合物的合成，这些化合物源自甲基吡啶-2,4-二氧丁酸酯，含有与取代的生物活性杂环基团相连的吡啶环，以调查其初步的体外抗菌和抗真菌活性。结果显示，大多数测试的化合物对铜绿假单胞菌（P. aeruginosa）和大肠杆菌（E. coli）表现出显著活性。它们还对金黄色葡萄球菌（S. aureus）和枯草芽孢杆菌（B. subtilis）显示了相当的活性。另一方面，这些化合物表现出中等的抗真菌活性。

  DOI：

  10.2174/1573406411666141205102544
• 作为产物：
  描述：

  草酸二甲酯 、 4-乙酰吡啶 在 sodium methylate 作用下， 以 甲醇 为溶剂， 生成 2,4-二氧代-4-吡啶-4-丁酸甲酯
  参考文献：
  名称：

  [EN] PYRAZOLE DERIVATIVES FOR TREATING CONDITIONS MEDIATED BY ACTIVATION OF THE ADENOSINE A2B OR A3 RECEPTOR
  [FR] COMPOSES ORGANIQUES

  摘要：

  公开号：

  WO2006015860A3

文献信息

• Design, Synthesis and Biological Screening of Some Pyridinylpyrazole and Pyridinylisoxazole Derivatives as Potential Anti-inflammatory, Analgesic, Antipyretic and Antimicrobial Agents
  作者：Soad El-Hawash、Raafat Soliman、Amal Youssef、Hanan Ragab、Perihan Elzahhara、Ibrahim El-Ashmawey、Abeer Abdel Wahab、Iman Shaat

  DOI：10.2174/15734064113096660044

  日期：2014.3.31

  A series of substituted pyridinylpyrazole (or isoxazole) derivatives were synthesized and evaluated for their anti-inflammatory (AI) activity using formalin-induced paw edema bioassays. Their inhibitory activities of cyclooxygenase-1 and cyclooxygenase-2 (COX-1 and COX-2) were also determined. The analgesic activity of the same compounds was evaluated using rat-tail withdrawal technique. Their antipyretic activity was also evaluated. The results revealed that compounds 4a,b, 6a, 8a, 14c and 15a exhibited significant AI and analgesic activities. Compounds 5a, 6a and 8a displayed good antipyretic activity. Compounds 14c and 15a showed good COX-2 inhibitory activity and weak inhibition of COX-1. Additionally, the most active compounds were shown to have a large safety margin (ALD50 300-400 mg / Kg) and minimal ulcerogenic potentialities when administered orally at a dose of 300 mg/Kg. Docking studies for 14c and 15a with COX-2 showed good binding profile. Antimicrobial evaluation proved that most of the compounds exhibited distinctive activity against the gram negative bacteria, P. aeruginosa and E coli.

  一系列取代的吡啶基吡唑（或异噁唑）衍生物被合成并评估其抗炎（AI）活性，采用福尔马林诱导的爪部水肿生物测定法。同时，还确定了它们对环氧化酶-1和环氧化酶-2（COX-1和COX-2）的抑制活性。采用大鼠尾部撤回技术评估了相同化合物的镇痛活性。还评估了它们的退烧活性。结果显示，化合物4a、4b、6a、8a、14c和15a表现出显著的抗炎和镇痛活性。化合物5a、6a和8a显示出良好的退烧活性。化合物14c和15a表现出良好的COX-2抑制活性，而对COX-1的抑制较弱。此外，最活跃的化合物在口服300 mg/Kg剂量下显示出较大的安全边际（ALD50 300-400 mg/Kg）和最小的溃疡生成潜力。与COX-2的对接研究显示化合物14c和15a具有良好的结合特性。抗菌评估证明大多数化合物对革兰氏阴性细菌（如铜绿假单胞菌和大肠杆菌）表现出显著活性。
• [EN] SUBSTITUTED PYRROLIDINONE AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE<br/>[FR] PYRROLIDINONE SUBSTITUÉE EN TANT QU'INHIBITEURS DE LA POLYMÉRASE DU VIRUS DE L'HÉPATITE C NS5B, COMPOSITION PHARMACEUTIQUE LA COMPRENANT ET LEUR UTILISATION THÉRAPEUTIQUE
  申请人：VIVALIS

  公开号：WO2011004018A1

  公开（公告）日：2011-01-13

  The present invention concerns a substituted pyrrolidinone of the following formula I or a salt, solvate, tautomer, isotope, enantiomer, diastereoisomer or racemic mixture thereof:(I), for the treatment of hepatitis C.

  本发明涉及以下式I的取代吡咯烷酮或其盐、溶剂合物、互变异构体、同位素、对映体、非对映异构体或其外消旋混合物，用于治疗丙型肝炎。
• SUBSTITUTED PYRROLIDINONE AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE
  申请人：Berecibar Amaya

  公开号：US20120189579A1

  公开（公告）日：2012-07-26

  The present invention concerns a substituted pyrrolidinone of the following formula I or a salt, solvate, tautomer, isotope, enantiomer, diastereoisomer or racemic mixture thereof: (I), for the treatment of hepatitis C.

  本发明涉及以下式I的取代吡咯烷酮或其盐、溶剂合物、互变异构体、同位素、对映异构体或其外消旋混合物，用于治疗丙型肝炎。
• Synthesis, molecular structure and multiple biological activities of N-(3-methoxyphenyl)-3-(pyridin-4-yl)-1H-pyrazole-5-carboxamide
  作者：Rajendran Nithyabalaji、Hariharasubramanian Krishnan、Rajendran Sribalan

  DOI：10.1016/j.molstruc.2019.02.095

  日期：2019.6

  A new molecule of pyridylpyrazole amide (PPA) was successfully synthesized and systematically characterized by using NMR, ESI-MS and absorption (FT-IR and UV-Vis) spectroscopic techniques. The UV-Vis spectral absorption and infrared frequencies were theoretically calculated and compared with observed results. The in vitro biological applications like anti-inflammatory, antioxidant and antidiabetic activities were performed. It exhibited admirable anti-inflammatory activity and antidiabetic, worthy antioxidant activities than standards. The interactions between enzyme-ligand were identified with alpha-amylase (1HNY.pdb) using the autodock tool. Further Potential energy scan, fukui function and molecular electrostatic potential (MEP) were performed using DFT methods. Finally, In silico pharmacological studies like ADME were implemented for PPA. (C) 2019 Elsevier B.V. All rights reserved.
• [EN] PYRAZOLE DERIVATIVES FOR TREATING CONDITIONS MEDIATED BY ACTIVATION OF THE ADENOSINE A2B OR A3 RECEPTOR<br/>[FR] COMPOSES ORGANIQUES
  申请人：NOVARTIS AG

  公开号：WO2006015860A3

  公开（公告）日：2006-06-15